Lilly Forecasts 2025 Profit Largely Above Estimates on Weight-Loss Drug Strength
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Peloton Stock Surges on Solid Revenue, Upbeat Adjusted Profit Forecast
Peloton Interactive shares jumped Thursday after the exercise equipment maker's second-quarter revenue and adjusted earnings forecast topped analyst estimates.
Bristol sees sharper 2025 revenue drop after better-than-forecast Q4
Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...